ORGO - Organogenesis Holdings Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Organogenesis Holdings Inc.

85 Dan Road
Canton, MA 02021
United States
781-575-0775
http://organogenesis.com

SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees700

Key Executives

NameTitlePayExercisedYear Born
Mr. Gary S. Gillheeney Sr.Pres, CEO & Director3.16MN/A1955
Ms. Lori H. FreedmanVP & Gen. Counsel496.25kN/A1967
Mr. Howard WalthallExec. VP of Strategy & Market Devel.571.53kN/A1972
Mr. Timothy M. CunninghamChief Financial OfficerN/AN/A1962
Mr. Patrick BilboChief Operating OfficerN/AN/A1962
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Corporate Governance

Organogenesis Holdings Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.